WPD Pharmaceuticals & Lizenzpartner

https://www.sedar.com/...p;projectNo=03216823&docId=4953084 

Da fragt man sich doch wieder, warum ?

aus dem 10-Q Filling vom Partner

" ... Recently reported data from our sponsored research demonstrates that in AML mouse models, the combination of Annamycin with Ara-C (a chemotherapy drug commonly used in AML patients) has a synergistic effect, suggesting that this combination may be more beneficial for AML patients than Annamycin as a single agent. Accordingly, we plan to begin a Phase 1/2 clinical trial of Annamycin in combination with Ara-C for the treatment of AML in Europe, by seeking approval for our own internally funded clinical trial in Europe and a second, similar trial through our sublicensee, WPD Pharmaceuticals, in Poland. Furthermore, we received U.S. Food and Drug Administration (FDA) clearance in late 2020 to proceed with a Phase 1b/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases and we are preparing to begin this internally funded trial in the US in the third quarter of 2021. Additionally, we expect in 2021 a second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases to be primarily investigator-funded in Europe ..."

Quelle: https://s3.amazonaws.com/content.stockpr.com/sec/...749-21-011755.pdf

Wurde nun was eingereicht oder nicht? Ich kann nichts finden.
So schafft man Vertrauen. Ob das mit WPD noch was wird? Mein Glaube daran schwindet, leider.